-

Agilent’s 2022 ESG Report Shows Progress Helping Customers Reach Their Sustainability Goals

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today released its 2022 ESG report on the company’s work supporting customers with their sustainability initiatives while advancing its own internal high-priority ESG programs, from reducing Scope 3 emissions in the value chain to cultivating a talented, diverse, and inclusive workforce.

“Agilent is committed to our customers’ success at every stage of their journey to bring great science to life,” said Agilent President and CEO Mike McMullen. “That includes helping them achieve their sustainability goals with our products, technology, and services. At the same time, we’re driving ESG objectives within our operations by fostering a great workplace, and investing in a diverse pipeline of talent, which is essential to our company’s future.”

The report also covers the role of Agilent products and technology in addressing some of society’s biggest challenges—from improving outcomes for cancer patients to helping measure exposure to substances such as PFAS.

Below are some of the highlights from fiscal 2022 in four focus areas of Agilent’s ESG program:

People

  • Earned Great Place to Work® certification in more than 20 countries and territories, based on strong results from an independent survey of employees.
  • Contributed $1 million to Delaware State University, a historically Black university, to fund scholarships for students pursuing STEM degrees; pledged an additional $3.5 million worth of state-of-the art instruments and supplies to equip the university’s new lab.
  • Launched two new employee networking groups (ENGs) to support both Hispanic and Asian Pacific Islander employees, adding to existing networking groups at Agilent to support Black, veteran, women, and LGBTQ+ employees.
  • Increased spending with diverse suppliers by 47 percent year over year, a key element of Agilent’s supplier diversity program.

Planet

  • Engaged suppliers in a plan to reduce Scope 3 emissions and submitted emissions-reduction targets to the Science Based Targets initiative for validation.
  • Reduced energy and water consumption intensity by 9.5 percent and 27.6 percent respectively, exceeding our targets in both areas.
  • Achieved 94 percent diversion of solid waste.
  • Launched a product life cycle assessment pilot study of an Agilent liquid chromatography instrument.
  • Implemented a formal sustainability function in Agilent’s Order Fulfillment division, which embeds sustainability into all aspects of manufacturing, supply chain, and logistics.

Products

  • Expanded sustainability offerings for our customers, including:
    • increasing the number of instruments that have earned the My Green Lab Accountability, Consistency, and Transparency (ACT) label;
    • adding How2Recycle labeling to product packaging;
    • achieving My Green Lab certification of Agilent customer demonstration labs;
    • introducing the HydroInert source for GC/MS, which runs on renewable hydrogen as the carrier gas, in place of non-renewable helium gas; and,
    • offering asset performance management software that can reduce lab energy use.
  • Refurbished 4,300 lab instruments through our award-winning Certified Pre-Owned Instruments Program, keeping decommissioned instruments out of landfills and substantially extending their life.

Prosperity

  • Invested $725 million in Agilent’s Frederick, Colorado, manufacturing facility to double production of therapeutic nucleic acids, which is expected to generate more than 160 life science jobs.
  • Donated $7.5 million in cash and in-kind contributions to support graduate students in STEM disciplines and academics working on innovative research that aligns with Agilent’s mission and business strategy.
  • Invested $7 million to upgrade Agilent’s R&D labs in Little Falls, Delaware, adding jobs to Agilent’s workforce in the state.

Agilent’s 2022 report also includes an updated Task Force on Climate-Related Financial Disclosures (TCFD) report, an index of materially relevant topics from the Global Reporting Initiative (GRI), and a SASB index. Read the report and related materials about Agilent’s ESG program at Agilent.com.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

Sarah Litton
+1 669 255 7696
sarah.litton@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Sarah Litton
+1 669 255 7696
sarah.litton@agilent.com

Social Media Profiles
More News From Agilent Technologies Inc.

Agilent Showcases Cancer Research Solutions at AACR 2026

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will present new technologies, scientific collaborations, and integrated workflows supporting cancer research and diagnostics at the American Association for Cancer Research (AACR) Annual Meeting on April 17–22, 2026, in San Diego, California. At the meeting, Agilent will highlight advances designed to connect discovery research, translational science, and companion diagnostics development, reflecting the growing demand f...

Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced the launch of the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation portfolio combining multimode microplate reading and high-content cell imaging in a single platform. Building on a decade of Cytation innovation and shaped by continuous customer feedback, the BioTek Cytation 9 helps laboratories move from samples to insights faster, supporting workflows from basic resea...

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to aid in identifying patients with esophageal or gastroesophageal junction (GEJ) carcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. PD-L1 IHC 22C3 pharmDx, Code SK006, is the only FDA-approved companion diagnostic indica...
Back to Newsroom